Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial

dc.contributor.author	Mesa, RA
dc.contributor.author	Vannucchi, AM
dc.contributor.author	Mead, A
dc.contributor.author	Egyed, Miklós
dc.contributor.author	Szoke, A
dc.contributor.author	Suvorov, A
dc.contributor.author	Jakucs, J
dc.contributor.author	Perkins, A
dc.contributor.author	Prasad, R
dc.contributor.author	Mayer, J
dc.contributor.author	Demeter, Judit
dc.contributor.author	Ganly, P
dc.contributor.author	Singer, JW
dc.contributor.author	Zhou, H
dc.contributor.author	Dean, JP
dc.contributor.author	te, Boekhorst PA
dc.contributor.author	Nangalia, J
dc.contributor.author	Kiladjian, J-J
dc.contributor.author	Harrison, CN
dc.date.accessioned	2021-09-27T09:41:08Z
dc.date.available	2021-09-27T09:41:08Z
dc.date.issued	2017
dc.identifier	85015784582
dc.identifier.citation	journalVolume=4;journalIssueNumber=5;journalTitle=LANCET HAEMATOLOGY;pagerange=e225-e236;journalAbbreviatedTitle=LANCET HAEMATOLOGY;
dc.identifier.uri	http://repo.lib.semmelweis.hu//handle/123456789/7267
dc.identifier.uri	doi:10.1016/S2352-3026(17)30027-3
dc.format.extent	e225-e236
dc.relation.ispartof	urn:issn:2352-3026
dc.title	Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial
dc.type	Journal Article
dc.date.updated	2019-07-18T11:06:39Z
dc.language.rfc3066	en
dc.rights.holder	NULL
dc.identifier.mtmt	3279806
dc.identifier.wos	000405451800011
dc.identifier.scopus	85015784582
dc.identifier.pubmed	28336242
dc.contributor.department	SE/AOK/K/I. Sz. Belgyógyászati Klinika
dc.contributor.institution	Semmelweis Egyetem